Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.
Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associa
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.
Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2
Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.
Denmark's Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs